References
1. Zoppini G., Targher G., Chonchol M., Ortalda V., Negri C., Stoico V., et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012; 7 (3): 401–8.
2. Mudaliar S., Polidori D., Zambrowicz B., Henry R.R. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport from bench to bedside. Diabetes Care. 2015; 38 (12): 2344–53. DOI: https://doi.org/10.2337/dc15-0642/-/DC1
3. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377 (7): 644–57. DOI: https://doi.org/10.1056/nejmoa1611925
4. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPA-REG outcome trial: A thrifty substrate hypothesis. Diabetes Care. 2016; 39 (7): 1108–14. DOI: https://doi.org/10.2337/dc16-0330
5. Mudaliar S., Alloju S., Henry R.R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care. 2016; 39 (7): 1115–22. DOI: https://doi.org/10.2337/dc16-0542
6. Heerspink H.J.L., Perkins B.A., Fitchett D.H., Husain M., Cherney D.Z.I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752–72.
7. Ceriello A., Genovese S., Mannucci E., Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016; 15 (1): 123.
8. Kalra S. Sodium-glucose cotransporter 2 (sglt2) inhibitors and cardiovascular disease: a systematic review. Cardiol Ther. 2016; 5 (2): 161–8.
9. Sattar N., McLaren J., Kristensen S.L., Preiss D., McMurray J.J. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016; 59: 1333–9.
10. Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968; 292 (7564): 363–6.
11. Karsdal M.A., Manon-Jensen T., Genovese F., Kristensen J.H., Nielsen M.J., Sand J.M.B., et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015; 308 (10): G807–30.
12. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7 (12): 684–96. DOI: https://doi.org/10.1038/nrneph.2011.149
13. Genovese F., Manresa A.A., Leeming D.J., Karsdal M.A., Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014; 7 (1): 4.
14. Gelse K., Pöschl E., Aigner T. Collagens–structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003; 55 (12): 1531–46.
15. Hewitson T.D., Holt S.G., Smith E.R. Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype – role of risk factors and epigenetics. Front Pharmacol. 2017; 8: 520. DOI: https://doi.org/10.3389/fphar.2017.00520/full
16. Park J., Scherer P.E. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest. 2012; 122 (11): 4243–56.
17. Sun K., Park J., Gupta O.T., Holland W.L., Auerbach P., Zhang N., et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 2014; 5 (3485): 1–12.
18. Mayer U., Poschl E., Nischt R., Specks U., Pan T., Chu M., et al. Recombinant expression and properties of the kunitz-type protease-inhibitor module from human type VI collagen a3 (VI) chain. Eur J Biochem. 1994; 225: 573–80.
19. Aigner T., Hambach L., Söder S., Schlötzer-Schrehardt U., Pöschl E. The C5 domain of col6a3 is cleaved off from the col6 fibrils immediately after secretion. Biochem Biophys Res Commun. 2002; 290 (2): 743–8.
20. Pilemann-Lyberg S., Rasmussen D.G.K., Hansen T.W., Tofte N., Winther S.A., Holm Nielsen S., et al. Markers of collagen formation and degradation reflect renal function and predict adverse outcomes in patients with type 1 diabetes. Diabetes Care. 2019; 42 (9): 1760–8.